

Inclusive Loss of Integrity of the Antitumor Immune Response as Chemokine Patterns of Nonrecognition

Agius LM*

Department of Pathology, Mater Dei Hospital, Tal-Qroqq, University of Malta, Medical School, Msida, Malta Europe

*Corresponding author:

Lawrence M Agius,
Department of Pathology, Mater Dei
Hospital, Tal-Qroqq, University of Malta,
Medical
School, Msida, Malta Europe,
Tel: 356-21451752,
E-mail: lawrence.agius@um.edu.mt

Received: 01 Apr 2021

Accepted: 17 May 2021

Published: 22 May 2021

Copyright:

©2021 Agius LM . This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and build upon your work non-commercially.

Citation:

Agius LM, Inclusive Loss of Integrity of the Antitumor Immune Response as Chemokine Patterns of Nonrecognition. *Ame J Surg Clin Case Rep.* 2021; 3(4): 1-3

1. Abstract

Forward participation of ongoing reformulation of tumor neoantigenicity is paramount consideration in the genesis of DC immaturity in the tumor microenvironment. In such terms, the hierarchical nature of DC migration abnormalities includes the patterns of interactivities of the innate with the adaptive immune systems as proposed by theoretical aspects of abnormal chemokine action. The various suppressive factors released by tumor cell pools call into consideration a relativity process of failed antigen processing and presentation by immature DC. The dimensions of non-operability of the substantial neoantigen recognition reflects the complexity of the tumor microenvironment within systems of template recognition. The incremental turnover of such chemokines reflects the abnormalities of turnover of the immature DC.

2. Introduction

The prerogative roles of Dendritic Cells (DC) are the derived range of a series of steps as pathway substantiation of antigen presentation as this latter conforms to the stimulated status of T helper and T cell cytotoxic cells. Lack of CD103+ DC within the tumor microenvironment dominantly resists effector status of an antitumor T cell response, leading to immune escape [1]. Such pathway roles include the derivation of factors secreted by tumor cells within an essential cytokine and chemokine context. The accumulation of tumor-specific T cells is promoted in tumors by dendritic cell vaccines and chemokine-modulation [2]. The context for stimulation of T cells in general is a realization of chemokine attraction of DC on the one hand and the evolutionary dimensions of incremental production of suppressive factors and of growth factors on the other. Macrophages polarized to a M2 phenotype and immature den-

dritic cells in tumors have a central role in subversion of adaptive immunity and inflammatory status that promote tumor growth and progression [3]. It is beyond simple cytokine production, however that there evolves the predetermination of proliferative events of tumor cells that induces the accumulation of immature DC in circulating blood and in the local tumor microenvironment.

3. Chemokine Failure

The dynamics of a failed chemokine series of induced events is paramount consideration in the understanding of the immune suppressive events during the establishment and progression of the tumor. Tumor production of prostaglandin E2 promotes evasion of the NK cell-conventional type 1 DC axis in part by impairing NK cell viability and chemokine formulation as well as by inducing down regulation of chemokine receptor expression in DC [4]. It is highly significant that the migratory dysfunctions are themselves the result of immaturity of the DC pools within such organs as lymph nodes and circulating blood. High 12-chemokine signature status is strongly associated with inflammation-related immune cells-related and apoptosis pathways, and more tumor-infiltrating immune cells such as cytotoxic T lymphocytes and myeloid dendritic cells [5]. The local tumor microenvironment is the target site for immature DC as well evidenced by such lesions as melanoma and head and neck squamous cell carcinomas.

4. Incremental Dimensions

The incremental dimensions of tumor induced immune suppressions are relative conducive elements that arise from a particularly specific phenomenon of abnormal migration of DC.

It is in such terms that evolution of tumor cell spread also invokes the deliberate predetermination of the modes of abnormal migra-

tion of immature DC within simple logistic dimensions of evolving immune suppression. The further provoking realization of the immature nature of DC is fundamentally derived through a whole series of dysfunctionality as proposed by pathways of inclusion dynamics of the local micro environmental milieu. Tumor-associated macrophages produce a large amount of CCL18 that is a marker of the M2 macrophage; this is related to immunosuppression in the tumor microenvironment and is important in cancer immune evasion [6].

5. Redistribution of Dendritic Cells

Pronounced distribution and redistribution dynamics incrementally permit the emergence of systems accentuation within ongoing chemokine action. Interleukin-15 enhances growth and activation of cytotoxic CD8+ T and NK cells; bioactive IL-15 comprises the IL-15 and IL-15 receptor alpha chains and delays tumor growth and promotes intratumor CTL and DC accumulation by a cytokine network involving XCL1, IFN-gamma, CXCL9 and CXCL10 [7]. In terms of such immaturity of DC there evolves an inability to establish contact direction of the DC with helper and cytotoxic T lymphocytes as confirmed by system biology of modeled suppression of the immune surveillance programs.

Such immune suppressive models are projected within shifting schemes of a tissue injury that combines the delivery of immature DC to the targeted tumor microenvironment.

The abnormal patterns of redistribution of DC account in large measure the immaturity of DC as these attempt transfer of antigenicity recognition to sensitized T lymphocytes. The cooperation between tumor-derived CCL5 and IFN-gamma-inducible CXCR3 ligands produced by myeloid cells is central to orchestrating T cell infiltration in immunoreactive and immunoresponsive neoplasms [8]. The ongoing dimensions of irrevocable model patterns include induced energy of the immune response as direct and indirect projection of incremental adaptation that is congruent with biology of entire integral pools of neoplastic cells that primarily spread and only consequently proliferate. Such a scenario evokes the semblance dynamics of interaction of innate with adaptive immune systems.

6. Coherent Immune Suppression

The coherence of immune suppression pathways primarily affects the DC in terms of both number and immaturity of these cells that accumulate within the tumor microenvironment. In such terms, ongoing phenomena of incipient reactivities owe much to the expression of chemokines.

The whole range of antigen presentation is an expression of late endosomal dysfunctions in the DC and indeed evidenced by abnormal intracellular processing of antigen that undergo uptake by the immature DC. The formidable dimensions of characterization and re-characterization of antigenicity profiles as exhibited by tu-

mor cells are also significant in terms of abnormal DC turnover within systems that fail to redefine multiple models of partly characterized antigenicity by these tumor cells. CC chemokine with an N-terminal CC domain important in immune system cells are significant in organ-specific metastasis and they also influence the recruitment of various cells to the tumor niche [9].

7. Contact Dynamics

Contact dynamics of the DC with T lymphocytes constitute a series of overlapping heterogeneities in the form of products of secretion by tumor cells. Hypoxia alters the expression of CC chemokine and CC chemokine receptors in neoplasms [10]. Failed co-stimulatory molecule production is an aspect for projection that likely provokes a suppression of turnover within the tumor microenvironment as well evidenced by systems of pooled immature DC. The incremental failure of recognition of neoantigenicity of proliferating tumor cells calls to operability the sustainability of template reorganization of co stimulatory molecules as projected by the immature DC.

8. Programmed Operability

Dimensions of operability are likely indices of a series of programmed events in mechanistically suppressing the antitumor immune response. In such terms, ongoing modulation of tumor cell antigenicity is a permissive cluster series of events that proceed in terms strictly of pathway recognition and progression. Chemokine receptor 9 and its exclusive ligand chemokine 26, are over expressed in many malignant lesions and closely related to tumor cell proliferation, apoptosis, invasion, migration and drug resistance [11]. The multi pathway constitution of antigen processing and presentation by DC is central to a whole series of hierarchical processes of non-resolution and would account for a process of dynamic turnover of DC in terms of end-result immaturity of these cells. Baseline cytokine levels may predict patients' outcome and treatment may influence kinetics even in end-stage cancer patients [12]. Prediction of overall survival and response to immune checkpoint inhibitors is an immune-related signature for gastric cancer [13].

9. Concluding Remarks

The deriving sustainability of the immaturity of DC that undergo turnover dynamics allows for the emergence of permissive microenvironment that locally reflects faithfully or less faithfully the incumbent promotion of abnormal DC migration to various systemic organs and regions within the body.

The promotional dimensions for modeled participation of tissue injury are permissive for the reconfirmed patterns of template predetermination of antigenicity recognition by the DC. Incremental turnover dynamics of DC is inherent predetermining of the nature dimensions of the tumor antigenicity that are brought forward by systems of interaction of innate with adaptive immune systems.

The proportionality of such antigenicity is integral to an immaturity of DC that preferentially involves the tumor microenvironment and as further propagated by abnormal chemokine actions and reactivities.

References

1. Spranger S, Dai D, Horton B, Gajewski TF. "Tumor-residing Batf3 dendritic cells are required for effective T cell trafficking and adoptive T cell therapy". *Cancer Cell*. 2017; 31(5): 711-723.
2. Obermajer N, Urban J, Wieckowski E, Muthuswamy R, Ravindranathan R, Bartlett DL, et al. "Promoting the accumulation of tumor-specific T cells in tumor tissues by dendritic cell vaccines and chemokine-modulating agents". *Nat Protoc*. 2018; 13(2): 335-357.
3. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. "Macrophage polarisation: tumor-associated macrophages as a paradigm for polarised M2 mononuclear phagocytes". *Trends Immunol*. 2002; 23(11): 549-55.
4. Bottcher JP, Bonavita E, Chakravarty P, Brees H, Cabeza-Cabrero M, Sammicheli S, et al. "NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control". *Cell*. 2018; 172(5): 1022-1037.
5. Tokunaga R, Nakagawa S, Sakamoto Y, Naseem M, Izumi D, Kosumi K, et al. "12-chemokine signature, a predictor of tumor recurrence in colorectal cancer". *Int J Cancer*. 2020; 147(2): 532-541.
6. Korbecki J, Olbromski M, Dziegiel P. "CCL18 in the progression of cancer". *Int J Mol Sci*. 2020; 21(21): 7955.
7. Berganaschi C, Pandit H, Nagy BA, Stellas D, Jensen SM, Bear J, et al. "Heterodimeric IL-15 delays tumor growth and promotes intra-tumor CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-gamma, CXCL9 and CXCL10". *J Immunother Cancer*. 2020; 8(1): e000599.
8. Dangaj D, Bruand M, Grimm AJ, Ronet C, Barras D, Duttagupta PA, et al. "Cooperation between constitutive and inducible chemokine enables T cell engraftment and immune attack in solid tumors". *Cancer Cell*. 2019; 35(6): 885-900.
9. Korbecki J, Grochans S, Gutowska I, Barczak K, Baranowska-Bosiacka I. "CC chemokines in a tumor: a review of pro-cancer and anti-cancer properties of receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 ligands". *Int J Mol Sci*. 2020; 21(20): 7619.
10. Korbecki J, Kojder K, Barczak K, Siminska D, Gutowska I, Chlubek D et al. "Hypoxia alters the expression of CC chemokine and CC chemokine receptors in a tumor—A literature review". *Int J Mol Sci*. 2020; 21(16): 5647.
11. Xu B, Deng C, Wu X, Ji T, Zhao L, Han Y, et al. "CCR9 and CCL25: a review of their roles in tumor promotion". *J Cell Physiol*. 2020; 235(12): 9121-9132.
12. Merlano MC, Abbona A, Paccagnella M, Falletta A, Granetto C, Ricci V, et al. "Cytokine profiling of end stage cancer patients treated with immunotherapy". *Vaccines (Basel)*. 2021; 9(3): 235.
13. Wang Z, Li X, Xu Y. "Prediction of overall survival and response to immune checkpoint inhibitors: an immune-related signature for gastric cancer". 2012; 14(6): 101082.